Official ESCRS | European Society of Cataract & Refractive Surgeons


Evaluation of a diffractive trifocal IOL in patients with previous myopic laser vision correction over a 12-month follow-up period

Search Title by author or title

Session Details

Session Title: Moderated Poster Session: Finding the Right Pseudophakic Presbyopia Treatment

Venue: Poster Village: Pod 2

First Author: : Y.Park SOUTH KOREA

Co Author(s): :                           

Abstract Details


To evaluate 1-year visual outcome and refractive stability of diffractive trifocal intraocular lens (IOL) implantation in patients with prior myopic laser vision correction.


Eye Love Eye Clinic, Seoul, South Korea.


Retrospective study of 32 eyes of 18 patients with prior myopic laser vision correction who had uncomplicated cataract surgery with the diffractive trifocal AT LISA® tri 839MP (Carl Zeiss Meditec AG, Jena, Germany). Visual acuity measurements were performed for uncorrected near (UNVA at 40cm), intermediate (UIVA, at 80cm) and distance vision (UDVA) at 1, 3, 6 and 12 months. The accuracy of Haigis-L formula was compared to Barrett True-K (no-history) and Shammas formula using an online calculator designed for post-refractive cataract patients.


Mean age of patients was 52.01±6.24 years. At the 1-year follow-up, UDVA, UIVA and UNVA were 0.74±0.15, 0.54±0.08 and 0.89±0.14 (decimal) respectively. Mean spherical equivalent at 1, 3, 6 and 12 months were -0.90±0.46, -0.93±0.46, -0.87±0.44 and -0.76±0.37. Barrett True-K and Haigis-L formulae had significantly smaller prediction errors compared to Shammas formula with mean refractive prediction errors of -0.27±0.38, -0.20±0.40 and -0.61±0.43 respectively. No patient required postoperative enhancement.


Trifocal implantation in patients with prior myopic refractive surgery is an excellent option to provide good levels of near, intermediate and distance vision. When choosing the IOL power, Haigis-L and Barrett True-K formula should be considered to provide refractive stability for patients.

Financial Disclosure:


Back to previous